ChemicalBook > CAS DataBase List > Cenicriviroc

Cenicriviroc

Cenicriviroc Structure
Cenicriviroc
  • CAS No.497223-25-3
  • Chemical Name:Cenicriviroc
  • CBNumber:CB72627679
  • Molecular Formula:C41H52N4O4S
  • Formula Weight:696.94
  • MOL File:497223-25-3.mol
Cenicriviroc Property
  • Boiling point 913.5±65.0 °C(Predicted)
  • Density 1.17±0.1 g/cm3(Predicted)
  • storage temp. Store at -20°C
  • solubility DMF: 20 mg/ml; DMSO: 20 mg/ml; DMSO:PBS (pH 7.2) (1:1): 0.5 mg/ml; Ethanol: 5 mg/ml
  • form A crystalline solid
  • pka 12.96±0.70(Predicted)
  • color Light yellow to yellow
  • FDA UNII 15C116UA4Y
Safety
Hazard and Precautionary Statements (GHS)
  • Symbol(GHS)
  • Signal wordWarning
  • Hazard statements H302-H315-H319-H335
  • Precautionary statements P261-P264-P270-P271-P280-P301+P312-P330-P302+P352-P321-P304+P340-P305+P351+P338-P332+P313-P362+P364-P337+P313-P403+P233-P405-P501

Cenicriviroc Chemical Properties,Usage,Production

  • Description Cenicriviroc is a dual antagonist of chemokine receptor types 2 and 5 (CCR2/CCR5). The receptors are found on Kupffer cells and hepatic stellate cells, and preclinical studies suggest its anti-inflammatory and anti-fibrotic activity. In the phase 2b CENTAUR study, cenicriviroc treatment for 1 year failed to achieve the primary outcome of a decrease in NAFLD activity score by ≥2 points with no worsening of fibrosis. Nonetheless, one of the key secondary outcomes, improvement in liver fibrosis without worsening of NASH, was achieved in 20% in the treatment group, compared with 10% in the placebo group. Besides, cenicriviroc reduced the serum levels interleukin- 6, C-reactive protein and fibrinogen, suggesting its action on inflammation that may not be reflected by crude histological assessment. A phase 3 study is planned.
  • Uses Cenicriviroc is an experimental drug candidate for the treatment of HIV infection. It is an inhibitor of CCR2 and CCR5 receptors, allowing it to function as an entry inhibitor which prevents the virus from entering into a human cell.
  • Definition ChEBI: Cenicriviroc is a member of the class of benzazocines that is (5Z)-1,2,3,4-tetrahydro-1-benzazocine which is substituted by a 2-methylpropyl, N-{4-[(S)-(1-propyl-1H-imidazol-5-yl)methanesulfinyl]phenyl}carboxamide and 4-(2-butoxyethoxy)phenyl groups at positions 1, 5 and 8, respectively. It is a potent chemokine 2 and 5 receptor antagonist currently in development for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis (NASH). It has a role as a chemokine receptor 5 antagonist, an anti-HIV agent, a chemokine receptor 2 antagonist, an antirheumatic drug and an anti-inflammatory agent. It is a diether, a member of imidazoles, a sulfoxide, an aromatic ether, a secondary carboxamide and a benzazocine.
  • Clinical Use Cenicriviroc is a small molecule inhibitor of both CCR2 and CCR5, and has demonstrated safety in early trials of human patients afflicted with HIV-1, as well as a phase IIb trial (ClinicalTrials.gov NCT01338883). Cenicriviroc has also demonstrated therapeutic potential in animal models of liver fibrosis as well as renal fibrosis. A phase II trial of cenicriviroc in patients with NASH and liver fibrosis is planned to complete in late 2017 and (ClinicalTrials.gov NCT02217475). This trial, also called “CENTAUR: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects With Liver Fibrosis,” is a double-blind, placebo-controlled, randomized multinational study with the primary endpoint being histologic improvement of NASH activity score without worsening of fibrosis in patients with NASH and liver fibrosis. Results of this study are pending. An open label rollover extension study of participants in CENTAUR began in early 2017 and is ongoing (ClinicalTrials. gov NCT03059446).
    There is evidence that CCRs are important in fibrosis in the liver, lung and kidney. At least one molecule that inhibits CCRs has demonstrable safety in human subjects. As such, blockade of CCRs with molecules such as Cenicriviroc represent another potential therapeutic avenue for the treatment of fibrotic inflammatory bowel disease.
  • in vivo

    Cenicriviroc (≥20 mg/kg/day) significantly reduces monocyte/macrophage recruitment in vivo. At these doses, cenicriviroc shows antifibrotic effects, with significant reductions in collagen deposition, and collagen type 1 protein and mRNA expression across the three animal models of fibrosis. In the NASH model, cenicriviroc significantly reduces the non-alcoholic fatty liver disease activity score. Cenicriviroc treatment has no notable effect on body or liver/kidney weight[1].

  • IC 50 CCR5: 0.29 nM (IC50); CCR2: 5.9 nM (IC50); R5 HIV-1: 0.024-0.08 nM (IC50, in PBMCs); R5 HIV-2: 0.03-0.98 nM (IC50, in PBMCs)
Cenicriviroc Preparation Products And Raw materials
Raw materials
Preparation Products
Cenicriviroc Suppliers
Global(90)Suppliers
  • Supplier：
    BOC Sciences
  • Tel：+1-631-485-4226
  • Email：inquiry@bocsci.com
  • Country：United States
  • ProdList：19552
  • Advantage：58
  • Supplier：
    Career Henan Chemica Co
  • Tel：+86-0371-86658258<br/>+8613203830695
  • Email：laboratory@coreychem.com
  • Country：China
  • ProdList：30230
  • Advantage：58
  • Supplier：
    Alfa Chemistry
  • Tel：
  • Email：Info@alfa-chemistry.com
  • Country：United States
  • ProdList：24072
  • Advantage：58
  • Supplier：
    InvivoChem
  • Tel：+1-708-310-1919<br/>+1-13798911105
  • Email：sales@invivochem.cn
  • Country：United States
  • ProdList：6391
  • Advantage：58
  • Supplier：
    TargetMol Chemicals Inc.
  • Tel：
  • Email：support@targetmol.com
  • Country：United States
  • ProdList：38630
  • Advantage：58
  • Supplier：
    LEAPCHEM CO., LTD.
  • Tel：+86-852-30606658
  • Email：market18@leapchem.com
  • Country：China
  • ProdList：43340
  • Advantage：58
Cenicriviroc Spectrum
497223-25-3, CenicrivirocRelated Search:
  • 合成有机化合物配体
  • 抑制剂
  • C41H52N4O4S
  • 化合物CENICRIVIROC,10 MM DMSO 溶液
  • 化合物 CENICRIVIROC
  • (S)-8-(4-(2-丁氧基乙氧基)苯基)-1-异丁基-N-(4-(((1-丙基-1H-咪唑-5-基)甲基)亚磺酰基)苯基)-1,2,3,4-四氢苯并[B]氮杂环辛四烯-5-甲酰胺
  • 西尼昔洛韦
  • 497223-25-3
  • Cenicriviroc, 10 mM in DMSO
  • (S)-8-(4-(2-Butoxyethoxy)phenyl)-1-isobutyl-N-(4-(((1-propyl-1H-imidazol-5-yl)methyl)sulfinyl)phenyl)-1,2,3,4-tetrahydrobenzo[b]azocine-5-carboxamide , Cenicriviroc
  • (S)-8-(4-(2-Butoxyethoxy)phenyl)-1-isobutyl-N-(4-(((1-propyl-1H-imidazol-5-yl)methyl)sulfinyl)phenyl)-1,2,3,4-tetrahydrobenzo[b]azocine-5-carboxamide
  • TAK-652 or Cenicriviroc
  • (S,E)-8-(4-(2-butoxyethoxy)phenyl)-1-isobutyl-N-(4-(((1-propyl-1H-imidazol-5-yl)methyl)sulfinyl)phenyl)-1,2,3,4-tetrahydrobenzo[b]azocine-5-carboxamide
  • 1-Benzazocine-5-carboxamide, 8-[4-(2-butoxyethoxy)phenyl]-1,2,3,4-tetrahydro-1-(2-methylpropyl)-N-[4-[(S)-[(1-propyl-1H-imidazol-5-yl)methyl]sulfinyl]phenyl]-
  • TBR-652
  • TBR652
  • TBR 652
  • TAK-652; TBR-652; TAK652; TBR652; TAK 652; TBR 652
  • CS-2572
  • TAK-652; TAK652; TAK 652; TBR-652; TBR 652; TBR652; CENICRIVIROC.
  • Cenicriviroc(TAK652)
  • Cenicriviroc mesylate (TAK-652)
  • TAK652
  • Cenicriviroc

Home

My